Nexthera Capital LP bought a new stake in Magenta Therapeutics Inc (NASDAQ:MGTA) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 150,000 shares of the company’s stock, valued at approximately $2,025,000. Nexthera Capital LP owned approximately 0.46% of Magenta Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the stock. Point72 Hong Kong Ltd bought a new stake in Magenta Therapeutics in the 2nd quarter valued at about $109,000. Point72 Asset Management L.P. bought a new stake in Magenta Therapeutics in the 2nd quarter valued at about $109,000. Tiverton Asset Management LLC bought a new stake in Magenta Therapeutics in the 2nd quarter valued at about $125,000. Dean Capital Investments Management LLC bought a new stake in Magenta Therapeutics in the 2nd quarter valued at about $558,000. Finally, Platinum Investment Management Ltd. bought a new stake in Magenta Therapeutics in the 2nd quarter valued at about $675,000. 30.27% of the stock is owned by institutional investors and hedge funds.

In related news, Director David Scadden purchased 6,600 shares of the business’s stock in a transaction on Monday, June 25th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $99,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

MGTA has been the subject of a number of analyst reports. Cowen initiated coverage on Magenta Therapeutics in a research note on Monday, July 16th. They set an “outperform” rating for the company. Wedbush initiated coverage on Magenta Therapeutics in a research note on Monday, July 16th. They set an “outperform” rating and a $22.00 price target for the company. Goldman Sachs Group initiated coverage on Magenta Therapeutics in a research note on Monday, July 16th. They set a “buy” rating and a $18.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on Magenta Therapeutics in a research note on Monday, July 16th. They set an “overweight” rating and a $18.00 price target for the company.

MGTA stock opened at $12.00 on Friday. Magenta Therapeutics Inc has a 52-week low of $11.45 and a 52-week high of $16.33.

Magenta Therapeutics (NASDAQ:MGTA) last released its quarterly earnings results on Thursday, August 9th. The company reported ($3.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.10) by ($2.03). equities analysts anticipate that Magenta Therapeutics Inc will post -2.8 earnings per share for the current fiscal year.

About Magenta Therapeutics

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Featured Story: Stop Order Uses For Individual Investors

Institutional Ownership by Quarter for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.